Dexcel Pharma
Or Akiva, Israel· Est.
Israel’s leading private pharma, Dexcel delivers innovative and generic medicines worldwide with advanced manufacturing and R&D capabilities.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israel’s leading private pharma, Dexcel delivers innovative and generic medicines worldwide with advanced manufacturing and R&D capabilities.
Technology Platform
Combines traditional small‑molecule chemistry with biologics, oligonucleotide, and gene‑medicine platforms, supported by highly automated oral‑solid dosage manufacturing and advanced R&D infrastructure.
Opportunities
Expanding its innovative pipeline into high‑growth areas such as oncology and gene therapy while leveraging its large‑scale manufacturing capacity for global generic market share.
Risk Factors
Intense competition from multinational generics producers and regulatory challenges associated with biologics and gene‑therapy development.
Competitive Landscape
Dexcel competes with both global generic manufacturers and emerging biotech firms; its differentiation stems from integrated manufacturing, extensive R&D capabilities, and a diversified product portfolio.